Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST) Meeting Abstract
| Authors: | Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; Kieslich, P.; Motzer, R. J. |
| Abstract Title: | Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1017 |
| End Page: | S1018 |
| Language: | English |
| ACCESSION: | WOS:001326612902320 |
| DOI: | 10.1016/j.annonc.2024.08.1791 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1698P -- Source: Wos |
